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Summary Trachoma is the commonest infectious cause of blindness. Recurrent episodes of infection with serovars
A–C of Chlamydia trachomatis cause conjunctival inflammation in children who go on to develop
scarring and blindness as adults. It was estimated that in 2002 at least 1.3 million people were blind from
trachoma, and currently 40 million people are thought to have active disease and 8.2 million to have
trichiasis. The disease is largely found in poor, rural communities in developing countries, particularly in
sub-Saharan Africa. The WHO promotes trachoma control through a multifaceted approach involving
surgery, mass antibiotic distribution, encouraging facial cleanliness and environmental improvements.
This has been associated with significant reductions in the prevalence of active disease over the past
20 years, but there remain a large number of people with trichiasis who are at risk of blindness.
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Introduction
Trachoma is the leading infectious cause of blindness
worldwide. It is caused by infection with Chlamydia
trachomatis and is characterised by inflammatory changes
in the conjunctiva in children with subsequent scarring,
corneal opacity and blindness in adults. The World Health
Organization (WHO) estimated in 2002 that 1.3 million
people were blind from trachoma (Resnikoff et al. 2004)
and it is likely that a further 1.8 million were suffering
from low vision (Frick et al. 2003a). Many of the
additional 1.9 million cases of blindness from ‘corneal
opacities’ were also likely to be because of trachoma in
areas where it is endemic (Resnikoff et al. 2004). The
number of people with active disease is estimated to be 40
million, and the number with trichiasis, 8.2 million
(Mariotti et al. 2009). Trachoma is an ancient disease and
has previously been a significant public health problem in
many areas of the world including parts of Europe and
North America. Today, however, trachoma is largely
found in poor, rural communities in low-income countries,
particularly in sub-Saharan Africa. In 1998, the WHO
established the Alliance for the Global Elimination of
Blinding Trachoma by 2020 (GET2020). This promotes
trachoma control through the SAFE Strategy: surgery for
trichiasis, antibiotics for C. trachomatis infection, facial
cleanliness and environmental improvement. Where con-
trol measures have been implemented encouraging reduc-
tions in the prevalence of trachoma have been found.
Historical perspective
The earliest references to trachoma come from China in the
27th century BC (Al-Rifai 1988). Features of trachoma
were also described in the Ebers papyrus from Egypt, 15th
century BC, and epilation forceps discovered in tombs from
the 19th century BC (Maccallan 1931, Hirschberg 1982).
Trachoma became a major public health problem in
Europe at the beginning of the 19th century, when the
disease was believed to have been brought back by troops
returning from the Napoleonic wars in Egypt. So great was
the burden of the disease at that time that many of the
major ophthalmic hospitals founded in the 19th century
were established to treat trachoma, including Moorfields
Eye Hospital and Massachusetts Eye and Ear Infirmary. By
the end of the 19th century, immigrants to the United
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States were routinely screened for trachoma and sent home
if they had signs of the disease. Trachoma has now
disappeared from developed countries (with the exception
of Aboriginal communities in outback Australia (Tellis
et al. 2007), probably as a result of general improvements
in living and hygiene standards.
Clinical features and natural history
Trachoma is a chronic keratoconjunctivitis caused by
recurrent infection with serovars A, B, Ba and C of
C. trachomatis. Infection is most commonly found in
children. With repeated reinfection, some people go on to
develop scarring complications and blindness in later life.
The clinical manifestations of trachoma are subdivided
into those associated with ‘active’ disease, usually seen in
childhood, and those associated the cicatricial or scarring
complications, seen in late childhood and adults (Figure 1).
Active disease is characterised by recurrent episodes of
chronic, follicular conjunctivitis. Follicles are subepithelial
collections of lymphoid cells and appear as small, yellow-
white elevations on the conjunctiva of the everted upper
lid. Papillary hypertrophy (engorgement of small vessels
with surrounding oedema) also occurs and can obscure the
deep tarsal vessels if severe enough. Vascular infiltration of
the upper cornea (pannus) may also develop in active
disease, but this rarely affects vision. Individuals are
frequently asymptomatic or have only mild symptoms even
if marked signs of inflammation are evident. If present,
symptoms are similar to those associated with any chronic
conjunctivitis: redness, discomfort, tearing, photophobia
and scant muco-purulent discharge. Conjunctival follicles
at the upper margin of the cornea leave shallow depres-
sions after they resolve known as ‘Herbert’s pits’ which,
unlike follicles and papillae, are a pathognomonic sign of
trachoma.
Repeated and prolonged episodes of infection and
inflammation can result in the scarring complications of
trachoma. Initially, conjunctival scarring is seen in the
subtarsal conjunctiva, which can range from a few linear or
stellate scars to thick, distorting bands of fibrosis. Con-
traction of this scar tissue causes entropion (in-turning of
the eyelids) and trichiasis (eyelashes touching the eyeball)
which is often painful. Eventually, corneal opacification
develops the blinding end-stage of the disease. This is
probably a result of multiple insults to the cornea:
mechanical trauma from lashes, secondary bacterial or
fungal infection and a dry ocular surface.
Over the years, various grading systems for trachoma
have been proposed. The one which is currently used by
trachoma control programmes is the 1987 WHO simplified
grading system (Table 1) (Thylefors et al. 1987).
The prevalence of active disease is highest in pre-school
children and declines to low levels in adulthood (Dawson
et al. 1976; West et al. 1991b; Dolin et al. 1998). This
parallels the distribution of C. trachomatis infection, with
up to half of the community bacterial load being found in
children under the age of 1 year in some studies (Solomon
et al. 2003; Melese et al. 2004b). Adult bacterial loads are
usually lower than those of children, and the duration of
infection and disease also declines with age, presumably as
the result of an acquired immune response (Bailey et al.
1999; Grassly et al. 2008). This is in contrast to the
scarring features of trachoma, the prevalence of which
(a)
(c)
(b)
(d)
Figure 1 Clinical features of trachoma.
(a) Active trachoma in a child, characterised
by a mixed papillary (TI) and follicular
response (TF). (b) Tarsal conjunctival
scarring (TS). (c) Entropion and trichiasis
(TT). (d) Blinding corneal opacification
(CO) with entropion and trichiasis (TT).
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increase with age, reflecting the cumulative nature of the
damage. Where the prevalence of active disease is very
high, cicatricial complications may be seen at an early age;
trichiasis was reported in 2–3% of children under the age
of 15 years in southern Sudan where the prevalence of
active disease was 70–80% (Ngondi et al. 2006a; King
et al. 2008).
Cohort studies in trachoma-endemic communities in The
Gambia and Tanzania have looked at the progression of
the scarring process:
• Worsening of conjunctival scarring was seen in nearly
50% of scarred subjects over 5 years (Tanzania)
(Wolle et al. 2009).
• Progression from conjunctival scarring to trichiasis
was seen in 10% after 7 years and 6% after 12 years
(Tanzania and The Gambia) (Munoz et al. 1999;
Bowman et al. 2001).
• Minor trichiasis (<5 lashes touching the eye) pro-
gressed to major trichiasis (five or more lashes
touching the eye) in 33% after 1 year and in 37%
after 4 years; and unilateral progressed to bilateral
trichiasis in 46% after 1 year (The Gambia) (Bowman
et al. 2002b; Burton et al. 2006).
• Trichiasis is associated with the development of
corneal scarring: 8% of people with trichiasis devel-
oped incident corneal scarring after 4 years, and there
was worsening of established corneal scarring in 34%
after 1 year (The Gambia) (Bowman et al. 2002b;
Burton et al. 2006).
The first study from Tanzania had a standardised,
prospective design but the others did not. There is
considerable variation in the reported rates of progression,
which may reflect both variation in progression rates in
different populations and methodology. A key determinant
of the rate of disease progression is probably the burden of
C. trachomatis infection in a community over time,
although the direct evidence for this is limited. Several
studies found that the risk of developing scarring compli-
cations is greater in those with recurrent or persistent
severe inflammatory trachoma (Dawson et al. 1990;
Munoz et al. 1999; West et al. 2001; Burton et al. 2006).
Infection vs. disease
There is little doubt that C. trachomatis is the cause of
trachoma; Koch’s postulates were largely fulfilled shortly
after the first isolation of C. trachomatis in 1957 (Tang
et al. 1957; Collier et al. 1958). However, C. trachomatis
cannot be detected in all cases of active disease, even using
highly sensitive nucleic acid amplification tests (NAAT)
(Baral et al. 1999; Lietman et al. 2000; Burton et al. 2003;
Miller et al. 2004b). In low prevalence communities,
especially those that have received mass antibiotic treat-
ment, C. trachomatis is only found in a minority of those
with active disease. Those with intense trachomatous
inflammation are more likely to be infected and have
higher bacterial loads than those with follicular disease
(Burton et al. 2003; Solomon et al. 2004b; Wright &
Taylor 2005). In endemic communities infection is some-
times detected in those who do not fulfil the WHO criteria
for active disease. Part of the explanation for this poor
correlation is likely to be the kinetics of the disease with a
short latent phase (infection before clinical signs with the
incubation period for disease), a patent phase (infection
and clinical signs) and a recovery phase (infection cleared
but clinical signs persist, which can last for many months)
(Bailey et al. 1994; Wright et al. 2008). The mismatch
between the presence of infection and clinical findings is
also partly explained by use of the simplified WHO grading
system, which excludes those with fewer than five follicles
in the subtarsal conjunctiva (Ward et al. 1990).
Transmission of Chlamydia trachomatis infection
Chlamydia trachomatis is probably transmitted between
individuals by a variety of mechanisms, including:
• Direct spread from eye to eye during close contact
such as during play or sleep.
• Spread of infected ocular or nasal secretions on
fingers.
• Indirect spread by fomites such as infected face-
cloths.
Table 1 1987 WHO simplified trachoma grading (Thylefors et al.
1987)
Grade Description
Trachomatous
inflammation – Follicular
TF The presence of five or more
follicles (each >0.5 mm in
diameter) in the upper tarsal
conjunctiva
Trachomatous
inflammation – Intense
TI Pronounced inflammatory
thickening of the tarsal
conjunctiva that obscures
more than half of the deep
normal vessels
Trachomatous scarring TS The presence of scarring in the
tarsal conjunctiva
Trachomatous trichiasis TT At least one lash rubs on the
eyeball
Corneal opacity CO Easily visible corneal opacity
over the pupil
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• Transmission by eye-seeking flies.
• Possible spread from nasopharyngeal infection by
aerosol.
A combination of these and other transmission mecha-
nisms probably operates in most environments, although
their relative importance may vary. For example, in some
environments eye-seeking flies probably contribute to the
transmission of infection. Chlamydia trachomatis has been
detected by polymerase chain reaction in around 20% of
Musca sorbens caught on the faces of children in Ethiopia
(Jones 1975; Miller et al. 2004a; Lee et al. 2007) and
intervention trials to reduce fly density have been associ-
ated with a reduction in active trachoma in The Gambia
(Emerson et al. 1999, 2004). However, in other locations,
the density of eye-seeking flies is insignificant and does not
appear to contribute towards transmission (Taylor et al.
1985). Genital strains of C. trachomatis do not cause
endemic trachoma, although occasionally they cause a self-
limiting conjunctivitis (Brunham et al. 1990).
Trachoma is a focal disease and has been found to
cluster at the level of the community, the household and
within bedrooms, reflecting the infectious nature of the
disease and suggesting that prolonged intimate contact is
necessary for the transmission of infection (Dawson et al.
1976; Katz et al. 1988; Bailey et al. 1989; West et al.
1991b; Burton et al. 2003). This is particularly important
for trachoma control programmes, as it significantly
increases the sample size necessary for estimating the
prevalence within a region (Katz et al. 1988). Most
transmission events occur within the household, and a
failure to treat all infected household members during mass
antibiotic distribution may result in rapid re-infection of
that family followed by more gradual spread across the
community (Blake et al. 2009).
No non-human reservoir of infection has been found,
with flies only acting as passive vectors. The importance of
extra-ocular sites of infection has been debated. Chlamydia
trachomatis can be detected in secretions from the naso-
pharynx, and a recent study also showed that infected
nasal discharge in children at baseline was associated with
an increased risk of active disease and conjunctival
infection 2 months after systemic treatment (Malaty et al.
1981; West et al. 1993; Gower et al. 2006). However,
nasal swabs were taken only from children with visible
discharge and were of the discharge rather than from nasal
epithelium. Positive results may simply have been a
reflection of severe ocular infection which was not cleared
with one dose of antibiotic, with infected secretions passing
through the nasolacrimal ducts. An earlier study using
nasal swabs on all children showed that new ocular
infection after treatment was not related to a positive or
negative nasal specimen at baseline (West et al. 1993). In
addition, genotyping of conjunctival and nasal samples
from individuals with concurrent infection showed differ-
ent genotypes to be present, suggesting that auto-infection
was not an important factor (Andreasen et al. 2008).
Prevalence and geographical distribution
Trachoma is a major cause of blindness in many less-
developed countries, especially in poor, rural areas.
Blinding trachoma is believed to be endemic in over 50
countries, with the highest prevalence of active disease and
trichiasis in Africa, predominantly in the savannah areas of
East and Central Africa and the Sahel of West Africa
(Figure 2). It is also endemic in a number of countries in
the Middle East, Asia, Latin America and the Western
Pacific (Polack et al. 2005). Current WHO estimates for
the prevalence of active disease, trichiasis and blindness are
significantly lower than previous ones and declines in the
prevalence have been noted in several countries, but there
is considerable uncertainty around these estimates, as little
recent information is available from India and China.
About half of the global burden of active trachoma is
concentrated in five countries: Ethiopia, India, Nigeria,
Sudan and Guinea; while half of the global burden of
trichiasis is concentrated in three countries: China, Ethio-
pia and Sudan (Mariotti et al. 2009). Recent studies from
southern Sudan, previously inaccessible during the civil
war, have shown very high levels of trachoma: up to 80%
of children had active disease and one-fifth of adults had
trichiasis (Ngondi et al. 2006a; King et al. 2008). Tra-
choma was shown to account for 35% of blindness, with
5% of the entire population (including children) suffering
from low vision or blindness associated with trachoma
(Ngondi et al. 2006b, 2007).
Some caution is required in the interpretation of global
estimates of trachoma prevalence (Burton & Mabey 2009).
These have generally been produced with models that have
relied on the results of a limited number of surveys
conducted in a few endemic countries. Various assump-
tions and extrapolations are then made, which have
considerable potential for error, such as extrapolating data
from a single survey within a district to give the district-
level prevalence, and national averages being generated
from available district prevalence data. The six million
people estimated by the WHO to be blind from trachoma
in the 1990s was probably a substantial overestimate as
results were based on questionnaires reporting numbers of
people who might become blind without treatment
(Thylefors et al. 1995). More recent estimates have used
more reliable survey data.
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Notwithstanding the aforementioned limitations of the
available data, there does appear to be a downward
trend in the number of people affected by trachoma.
Improved living standards in many countries probably
account for at least part of this trend, as was the case
with the disappearance of trachoma from industrialised
countries a century ago (Dolin et al. 1997; Hoechsmann
et al. 2001). The establishment of trachoma control
programmes has probably played a major role, although
this is difficult to quantify. Worryingly, the number of
people estimated to have trichiasis has shown little
decline since 1991, with a slight increase estimated
between 2003 and 2008. This suggests that progressive
conjunctival scarring can occur even when there has been
a marked reduction in active disease and C. trachomatis
infection, which has long-term implications for control
programmes.
The most recent estimate from the WHO places the
burden of trachoma at 1.3 million disability-adjusted life
years. This measures the gap between a normal, healthy
population and the ‘cost’ of a disease from premature
mortality and disability (WHO 2008). The economic cost
of trachoma has been estimated at between US$ 3 billion –
8 billion in lost productivity (Frick et al. 2003a,b).
Estimates of the global burden of trachoma, however, are
faced with several problems including a lack of robust
prevalence data and the decision over inclusion of different
disease manifestations (Burton & Mabey 2009). Trichiasis
without visual impairment, for example, causes a level of
disability comparable to that caused by visual impairment
from non-trachomatous causes, yet it has not always been
included in disease burden calculations (Frick et al.
2001b).
Risk factors for trachoma
Many studies have examined potential risk factors for
trachoma, which have been previously reviewed (Emerson
et al. 2000; West 2004; Haylor 2008). Studies examining
the relationship between trachoma and various environ-
mental, socio-economic and behavioural factors are diffi-
cult to interpret as they often lack adequate controls and
are potentially confounded with many factors being closely
interrelated. For example, establishing what contribution a
dirty face makes to trachoma, or vice versa, is difficult, as
active disease may cause ocular ⁄nasal discharge, but
discharge may be an important route for transmission. In
addition, variability in survey methodology and question-
naires may not allow reliable comparisons between studies
(Emerson et al. 2000).
Trachoma is currently more common in dry areas, and
the relationship between water and trachoma has been
studied in several settings, with some conflicting results.
It is plausible that better access to water would improve
hygiene levels and reduce the transmission of infection.
Several studies have indeed found an association between
increased distance to water and the prevalence of active
disease (Mathur & Sharma 1970; Tielsch et al. 1988;
Taylor et al. 1989; West et al. 1989; Schemann et al.
2002). However, other studies have not supported this
and the association appears to be absent when the
distance to water is small (West et al. 1991b; Zerihun
1997; Kuper et al. 2003). This may be explained by the
presence of a ‘water use plateau’ in which per capita
water consumption between households often seems to
be constant when the round trip to collect water is
below a threshold of around 30 min (Cairncross &
Feachem 1993). The quantity of water brought into a
household may be more important than the distance to
water. Indeed, one study found the quantity to be
independent of distance and that children from house-
holds with a greater quantity of water had less active
disease (Kupka et al. 1968). However, other studies have
shown that after controlling for distance the total
quantity of water used had no effect on the prevalence of
disease (West et al. 1989; Bailey et al. 1991). The second
Trachoma Endemic Contries (known)
2009
Figure 2 Map of trachoma endemic
countries in 2009. Reproduced with
permission from Dr Silvio P. Mariotti,
WHO ⁄NMH ⁄ .
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of these two studies may unlock the key issue with
regard to water and trachoma: the authors actually
measured how much water was brought into the house
and also observed how the water was used. After
controlling for family size, distance to water and other
socio-economic factors, families with trachoma used less
water for washing children than did control families
without trachoma, regardless of the amount of water
available for consumption (Bailey et al. 1991).
The association between frequent face washing and
reduced trachoma has been reported in some, but not all,
studies (Taylor et al. 1985; Tielsch et al. 1988; Bailey
et al. 1991; Luna et al. 1992). Self-reporting may have
compromised the results, as washing may be perceived as
a desirable activity and hence over-reported. A
large-scale randomised trial of an intensive educational
intervention to encourage face washing in Tanzania
showed that children with a clean face were less likely to
have severe inflammatory trachoma (TI). However, there
was no reduction in the overall prevalence of active
trachoma and intensive behavioural intervention was
required (West et al. 1991a, 1995; Schemann et al.
2002).
As discussed previously, flies are also a risk factor for
trachoma by facilitating transmission. M. sorbens, the fly
most commonly found in contact with eyes, preferen-
tially breeds in human faeces. Latrine access is associated
with a lower risk of trachoma. This has been attributed
to the removal of faecal material from the environment
leading to a smaller fly population (Emerson et al. 2004).
Crowding is probably a risk factor for trachoma,
especially living in close proximity to children with active
disease (Bailey et al. 1989; Sahlu & Larson 1992). Women
tend to have a higher rate of the scarring complications
of trachoma and this is generally considered to be a
result of their increased contact with young children, the
main reservoir of infection (Turner et al. 1993).
Migration between communities may also be important in
the re-introduction of C. trachomatis (Burton et al.
2005b).
Assessing the burden of trachoma
Trachoma as a public health problem is defined by the
WHO as a prevalence of TF of at least 10% in children
aged 1–9, or a prevalence of TT of at least 1% in those
aged 15 or more. Trachoma is no longer considered a
public health problem when the TF prevalence in children
falls below 5% and the prevalence of TT is <0.1% (WHO,
1997; Kuper et al. 2003). No specific guidelines are
provided for areas where the prevalence falls between these
thresholds.
Population-based prevalence surveys (PBPS)
To determine where trachoma is a public health problem,
WHO recommends cluster random sampling (Ngondi
et al. 2009b). Districts likely to be trachoma-endemic are
identified using information from previous surveys, written
reports, hospital eye surgery records and interviewing
people with local experience. A list of all clusters within the
districts identified is made. Clusters are preferably areas of
approximately the same population size, so that the cluster
selection is with probability of selection proportional to
size. A random sample of clusters is then selected, which is
sufficiently large such that the sample prevalence of TF in
1–9 year olds, or TT in those aged 15 or more, reflects the
prevalence in the whole population (WHO, 2006). A two-
stage design can be employed, whereby villages (clusters)
are selected in the first stage, and households are selected in
the second. If household lists are not available, other
methods for selecting households are by random walk and
compact segment sampling. Reports should present stan-
dardisation of the examiners’ grading, the sample size
parameters, confidence intervals of the estimate, and
adjustment for clustering (Ngondi et al. 2009b). As well as
obtaining accurate estimates of TF and TT prevalence,
surveys should collect data on the number of public access
and surface water points in the district, and the proportion
of households that have access to latrines and that are
within 15 min walk of the nearest water source available
during the dry season. These data allow planning, moni-
toring and evaluation of control interventions (WHO,
2006).
Population-based prevalence surveys provide compre-
hensive prevalence data and are rightly considered the
‘gold standard’ for trachoma surveys (Wright et al. 2005).
Although they can be designed to provide precise preva-
lence estimates over wide areas, they generally do not give
accurate estimates at the cluster level, and the sampling
needs to incorporate large design effects (four or more)
arising from the focal nature of active trachoma and use
large numbers of clusters if they are not to overlook
hyperendemic clusters of disease (WHO-ITI, 2004).
Moreover, they are time consuming and expensive because
of the large sample sizes needed. Two alternative methods
have been proposed: trachoma rapid assessment (TRA) and
acceptance sampling TRA (ASTRA).
Trachoma rapid assessment
Trachoma rapid assessment was designed to allow simple,
fast and cost-effective assessment of active disease,
trichiasis and environmental risk factors. Existing data
are first used to identify areas that are likely to be
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trachoma-endemic. The burden of trichiasis, active disease
and associated risk factors is then assessed in these areas
(Negrel & Mariotti 1999). At least three, but no more than
seven, villages are selected per district, with priority given
to those areas ‘deemed most socio-economically disad-
vantaged’ (Wright et al. 2005). In these communities,
individuals with TT are identified, leading to a crude
estimate of TT prevalence. Fifty children aged 1–9 from at
least 15 households that ‘appear to have the lowest socio-
economic status’ are then assessed for TF and ⁄or TI.
Finally, a survey is performed to determine household level
trachoma risk factors.
Trachoma rapid assessment provides rankings rather
than prevalence estimates, and the method of selection of
areas, communities and households outlined previously
will generally be subjective. This may lead to overestimated
and ⁄or inconsistent prevalence data, with the possible
extrapolation of biased data to the whole village and
district (Negrel et al. 2001; Myatt et al. 2003; Solomon
et al. 2004b). Evaluations of TRA rankings in comparison
to PBPS in Tanzania and China found comparable ranking
of communities, but TRA performed worse in low prev-
alence settings (Paxton 2001; Liu et al. 2002). However,
PBPS does not itself provide reliable estimates or rankings
for individual clusters, so these comparisons are flawed
(Ngondi et al. 2009b). In The Gambia, a study comparing
two TRA surveys found that active disease prevalence
estimates and rankings were inconsistent, indicating that it
is not a reliable method (Limburg et al. 2001).
Acceptance sampling TRA (ASTRA)
Acceptance sampling TRA, based on the principle of
sequential sampling methods, such as lot quality assurance
sampling (LQAS), has been proposed as an alternative to
TRA. A maximum sample size and an acceptable number
of TF cases are set and sampling stops when one of these is
met. Villages are classified as high prevalence if sampling is
stopped because the set number of TF cases was exceeded,
or as low prevalence where sampling is stopped because the
maximum sample size was reached (Myatt et al. 2003).
Thus, there is no fixed sample size. ASTRA was evaluated
in Malawi (Myatt et al. 2003) and Vietnam (Myatt et al.
2005) and found to be more reliable than TRA for the
prioritisation of communities with active disease.
The advantages of ASTRA are its speed and low cost as a
result of smaller sample sizes than are required for PBPS.
Sample sizes may, however, become large if the option of
continuing sampling in a lot until the maximum sample
size is met is taken, rather than stopping when the expected
number of TF cases is met (Ngondi et al. 2009b). ASTRA
may provide reliable TF prevalence estimates in individual
communities so long as the sample size is not too small
and, if combined with Centric Systematic Area Sampling,
may provide prevalence estimates over wide areas and
basic mapping of TF prevalence (WHO-ITI, 2004). How-
ever, LQAS sampling works best when the distribution of
cases is homogeneous (Anker et al. 1998), and when village
populations do not vary too much. Because trachoma
clusters both within communities and districts, an optimal
rapid and affordable strategy to take clustering into
account when choosing households and communities to
sample is still a challenge. In the mean time, PBPS remain
the only reliable source of prevalence data for trachoma,
and have generally been used to prepare national control
plans, and to forecast ultimate intervention goals for
surgery and antibiotic treatment.
Clinical signs versus infection
An additional concern with all of these survey methods is
their reliance on clinical signs as a measure of trachoma
prevalence. As mentioned previously, clinical signs are
sometimes poorly correlated with ocular C. trachomatis
infection, especially in low prevalence communities and
those that have received mass treatment. As three of the
four components of the WHO endorsed SAFE strategy for
the control of trachoma aim to interrupt transmission of
the bacteria, logic dictates that control measures should be
directed to areas with most infection. It has been suggested
that NAAT testing should be used to assess the prevalence
of ocular C. trachomatis infection in areas where the
prevalence of TF is <10% or between 10% and 20%
(Lansingh & Carter 2007). NAAT testing is not considered
necessary in higher prevalence areas as the correlation
between disease and infection is more reliable (Lansingh &
Carter 2007). However, NAAT testing is beyond the
budget of most trachoma control programmes, although
cost savings can be made by pooling samples from low
prevalence communities (Diamant et al. 2001). A simple
point of care test for C. trachomatis showed promise when
evaluated in trachoma-endemic communities in Tanzania
(Michel et al. 2006) but it is not yet commercially
available. Its sensitivity and specificity were lower when
evaluated in subsequent, larger studies in The Gambia and
Senegal (article in preparation).
Controlling trachoma: the SAFE strategy
Blindness from trachoma is essentially irreversible, but it
can be prevented. The Alliance for the Global Elimination
of Blinding Trachoma by the year 2020 (GET 2020) was
established by the WHO in 1997 and recommends the
SAFE strategy for trachoma control: Surgery for trichiasis;
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Antibiotics to treat C. trachomatis infection; Facial clean-
liness through personal hygiene; Environmental improve-
ment with education and improved local economy.
Surgery for trichiasis
The aim of surgery for trichiasis is to reduce the progres-
sion to corneal opacity and blindness as a result of lashes
abrading the cornea. Surgery has been shown to improve
comfort, reduce ocular discharge and improve visual acuity
in major trichiasis cases (Reacher et al. 1992; Bowman
et al. 2000a; Burton et al. 2005a). While trichiasis surgery
has not been directly shown to reduce the progression to
corneal opacity (Bowman et al. 2001, 2002b), the con-
sensus view is that there is some protective effect. The
WHO recommends regular surgical sessions at fixed sites
once a week, with periodic outreach stations held in
trachoma-endemic communities, and should be offered to
anyone with trichiasis, regardless of the number of
in-turned eyelashes (WHO, 2006).
What type of surgery?
Several procedures are in routine use by trachoma control
programmes. These generally involve a full thickness
incision through the tarsal plate combined with several
everting sutures to turn the distal part of the eyelid
outwards (Yorston et al. 2006). In a randomised controlled
trial, the bilamellar tarsal rotation (BLTR), which also
includes incision of the skin, was found to give the best
results of the procedures that were compared and therefore
WHO recommends this method (Reacher et al. 1992,
1993). The main alternatives in regular use are variations
of the posterior lamellar tarsal rotation (PLTR), including
the Trabut procedure. In the only study comparing
recurrence rates, no significant difference between BLTR or
PLTR was found (Adamu & Alemayehu 2002).
What are the challenges for surgery?
One of the major problems is high post-surgery trichiasis
recurrence rates, ranging from about 20% in the first
2 years (Reacher et al. 1992; Bog et al. 1993; Zhang et al.
2004a; Merbs et al. 2005; El Toukhy et al. 2006) to 60%
after 3 years (Reacher et al. 1993; Bowman et al. 2000a).
Several factors may contribute to recurrent trichiasis such
as the type of procedure used, the surgeon’s experience, the
severity of pre-operative disease (severe scarring and
entropion are associated with increased recurrence), suture
type and infection status (Reacher et al. 1992; Alemayehu
et al. 2004; Burton et al. 2005c; Merbs et al. 2005; El
Toukhy et al. 2006). The presence of conjunctival
inflammation, which may reflect ongoing inflammatory-
cicatricial responses, has been observed in patients with
trichiasis and conjunctival scarring and may be important
in the process of recurrent trichiasis. It is unclear what is
driving this process as infection with C. trachomatis is
relatively uncommon and has not been associated with
recurrent trichiasis (Burton et al. 2005c; West et al.
2006c). Other bacteria (non-chlamydial) are commonly
associated with trichiasis and so may contribute to
inflammation in the late stages of the disease (Burton et al.
2005c). To explore whether controlling infection improved
results, three randomised trials of post-operative azithro-
mycin have been conducted. These have given different
results. No effect was found in a low-prevalence Gambian
setting (Burton et al. 2005c), reduced recurrence was
observed in a high-prevalence Ethiopian settings (West
et al. 2007a), and reduced recurrence was observed for
major trichiasis, but increased recurrence for minor
trichiasis, in a medium-prevalence area of Nepal (Zhang
et al. 2006).
In many settings, the up-take of surgical services by
patients has been relatively low. Patient barriers include
cost, fear of surgery, transport difficulties, need for an
escort, lack of awareness about the need for treatment or
how to access care (Courtright 1994; West et al. 1994;
Bowman et al. 2002a; Melese et al. 2004a; Habte et al.
2008). It has been shown that community-based surgery
has greater attendance rates (66%) than health centre-
based surgery (44%) (Bowman et al. 2000c). Surgery is
therefore most successful when performed within the
community by a trained nurse, with little or no cost to the
patient (Mabey et al. 2003). Provider-level barriers include
lack of training, auditing, availability of sterilised equip-
ment and supplies and surgeons. To increase the number of
surgeons, ophthalmic nurses can be successfully trained
(Alemayehu et al. 2004). Case finding is of crucial impor-
tance and is facilitated by having individuals living in
endemic communities trained to recognise trichiasis and
refer cases (WHO, 2006).
Non-surgical alternatives
In many trachoma-endemic regions, epilation of the
eyelashes is commonly practised with home-made equip-
ment. For mild trichiasis with a few peripheral lashes in the
absence of significant entropion, this may be a reasonable
alternative to surgery; however, this has not yet been
formally tested. In a cross-sectional analysis before surgery,
epilation was associated with a reduced risk of corneal
opacification in people with more severe entropion but
made no difference for mild disease (West et al. 2006a).
A retrospective study showed that epilation neither helped
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nor hindered the progression process, although when
combined with hot ash there was more corneal damage
(Bowman et al. 2002b). Eyelid-taping has also been
proposed as a non-surgical intervention, but this is
generally a short-term measure prior to surgery (Yorston
et al. 2006). Nevertheless, eyelid-taping alone is more
effective than a single episode of epilation at keeping lashes
off the eye at 3 months (Graz et al. 1999).
Antibiotics
The demonstration that a single oral dose of azithromycin
was as effective as 6 weeks of daily tetracycline ointment
in the treatment of active disease was a major advance
(Bailey et al. 1993) and led directly to the launching of the
global elimination initiative. Mass treatment of whole
districts or communities is recommended, as this is more
effective in preventing reinfection than the treatment of
individual cases (Schachter et al. 1999). The WHO criteria
for deciding whether or not to treat are shown in Table 2.
A district is defined as a geographical area containing
between 100 000 and 150 000 people.
Which antibiotic?
The WHO recommends two antibiotic treatment regimes:
either 1% tetracycline eye ointment twice daily for 6 weeks
or a single oral dose of azithromycin. Randomised
controlled trials comparing these two treatments demon-
strated that they are equally efficacious (Bailey et al. 1993;
Tabbara et al. 1996; Dawson et al. 1997; Schachter et al.
1999) but that azithromycin is more effective in opera-
tional use (Bowman et al. 2000b). Tetracycline is almost
universally available but suffers from poor compliance
because of the length of administration, being difficult and
unpleasant to apply, and side-effects such as stinging and
blurred vision (West 1999; Kuper et al. 2003). Azithro-
mycin is well tolerated by both adults and children, has
good compliance, and has fewer side-effects than tetracy-
cline (Schachter et al. 1999; West 1999). It is also active
against extra-ocular C. trachomatis. A recent cluster-
randomised trial in Ethiopia showed that at 12 months,
there was a 50% reduction in childhood mortality in
communities where children had been treated with oral
azithromycin compared to those where they had not (Porco
et al. 2009). Pfizer has donated 135 million doses of
azithromycin for use in control programmes, distributed by
the ITI. The ITI is active in 18 trachoma-endemic coun-
tries. Azithromycin dosage is based on weight for children
(20 mg ⁄kg body weight), with adults receiving 1 g. As
weighing scales need daily calibration, are cumbersome to
carry, and the cooperation of young children can be hard
to obtain, height as a surrogate for weight has been
suggested and proved successful for dosing (Munoz et al.
2003).
Azithromycin for trachoma control is not currently
recommended for children under 6 months or pregnant
women, and therefore tetracycline ointment is the treat-
ment of choice for these groups. However, azithromycin is
recommended by the Centre for Disease Control in infants
under 1 month for pertussis prophylaxis (Tiwari et al.
2005) and is also recommended for the treatment of genital
chlamydial infection in pregnant women (Gray et al. 2001;
Pitsouni et al. 2007). The treatment of infants is important
as infants under 1 year have the highest bacterial load, as
discussed previously.
While oral azithromycin would seem to be a safe option,
a potential alternative is azithromycin eye drops. A clinical
trial of short duration azithromycin eye drops found that at
2 months, the cure rate and safety of topical 1.5%
azithromycin was non-inferior to oral azithromycin
(Cochereau et al. 2007), and mass treatment with the eye
drops of a district in Cameroon saw the prevalence of
active disease fall from 31.5% before treatment to 6.3%
1 year after treatment (Huguet et al. 2010).
As with any antibiotic, there are concerns that wide-
spread use might lead to drug resistance. Azithromycin
resistance has not yet been observed in C. trachomatis
(Solomon et al. 2005; Hong et al. 2009), but resistance in
other bacteria, such as Streptococcus pneumoniae, has
been documented, especially after multiple rounds of mass
treatment (Leach et al. 1997; Chern et al. 1999; Gaynor
et al. 2005) although this disappeared within 12 months of
treatment (Fry et al. 2002; Gaynor et al. 2003a). The
clinical relevance of this resistance has yet to be deter-
mined. It has been argued that in communities where
Table 2 WHO criteria for mass antibiotic treatment distribu-
tion(WHO-ITI 2004)
Prevalence of
TF in children
1–9 years Recommendation
District level
‡10% Mass treat whole district annually
for 3 years, then re-assess the
prevalence in the district
<10% Do community-level assessment
Community level
‡10% Mass treat whole community annually
for 3 years, then re-assess the
prevalence in the community
‡5% but <10% Target treatment to affected children
and the household they live in
<5% Antibiotic treatment not recommended
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macrolide resistance is rare, mass treatment with azithro-
mycin is unlikely to increase the prevalence of resistant
S. pneumoniae (Batt et al. 2003). Nasopharyngeal
S. pneumoniae resistance to topical tetracycline has also
been detected (Gaynor et al. 2005). The risk of drug
resistance highlights the need for sensitive diagnostic tests,
where treatment can be targeted to limit the over-use of
antibiotics within the mass treatment policy (Mabey et al.
2003).
To whom should treatment be given?
The optimal strategy of mass antibiotic treatment is subject
to some debate and probably varies depending on the
prevalence. Alternative treatment target groups have been
proposed:
• All children under 10 years old, because children are
the main reservoir of infection (Holm et al. 2001;
Solomon et al. 2003, 2004a). Frequent mass treat-
ment of all children under 11 years has shown herd
protection in the entire community in high-prevalence
settings (House et al. 2009).
• All people living in a household containing an
individual with active disease (Holm et al. 2001;
Burton et al. 2003; Blake et al. 2009).
• All people living in a community (e.g. village), where
the prevalence of active disease rises above a specific
threshold (Burton et al. 2003).
• Children with active disease and other children
residing with the TF ⁄TI child more than 50% of the
time (Laming et al. 2000).
• All TI individuals, as they have the highest number of
chlamydial DNA copies per swab (Solomon et al.
2003).
• Only infected individuals, as this would remove the
source of infection from the community, but this
requires the means to detect infection in the field
(Lietman et al. 1999).
In a study from a low-prevalence setting in The Gambia
in which the residents of 14 villages were examined and
tested for C. trachomatis infection, the theoretical effec-
tiveness of several strategies in delivering antibiotic to
infected individuals was compared (Burton et al. 2003). If
only the individuals with active trachoma were treated,
then only 24% of infected people would receive antibi-
otic. If treatment was targeted to all the residents of a
household where at least one case of active trachoma was
found, then 96% of infections would be treated. How-
ever, the number of people needed to be treated for each
infection case was 9.6. Finally, if all villages with more
than 15% active disease in children were treated, then
90% of infections would have been treated and the
number needed to treat was 5.4. Thus, for a low-to-
medium prevalence setting, community level treatment,
determined by the prevalence of active disease in the
children, appears to be a relatively efficient approach.
In a high-prevalence village in Tanzania, it was estimated
that if only children under 10 years were treated, only 69%
of those with high loads would be treated. If all members of
households with children aged <10 years were treated,
90% of the entire population would be treated because
most people live in households with children. Treating only
those with clinical signs would miss 23% of those with
high loads. The authors concluded that it is therefore more
practical and effective to treat the entire community, so
long as coverage is high enough (West et al. 2005a).
Mass treatment is considered the most cost-effective
strategy, especially in high-prevalence areas (Frick et al.
2001a; Holm et al. 2001). Targeted treatment strategies
require all children to be examined, which can be expensive
and time consuming. In addition, re-infection is more likely
to occur, as those treated may be re-infected by untreated
individuals (West et al. 1993). Mass treatment has the
advantage that all infected individuals are captured
(Schachter et al. 1999; Solomon et al. 2004a; West et al.
2005a). This is important, as clinical signs are not reliable
as a basis for targeted treatment (Baral et al. 1999),
asymptomatic individuals act as a reservoir of infection
(Burton et al. 2003; West et al. 2005a) and adults can also
act as an important reservoir of high load infection (West
et al. 2005a).
What treatment coverage should be achieved?
WHO recommends that treatment coverage should be
between 80% and 90% (WHO, 2004). Mathematical
modelling assuming 80% treatment coverage and 3 years of
annual treatment demonstrated elimination of infection in
95% of communities (Ray et al. 2009). In contrast, data
from Tanzania demonstrated that despite overall treatment
coverage of 86%, ocular C. trachomatis infection remained
in the community for up to 18 months after treatment,
albeit at a low level (Burton et al. 2005b). Much of the near
elimination of ocular C. trachomatis infection at 2 years
after a single round of azithromycin mass treatment in a
Tanzanian community has been attributed to the 97.8%
treatment coverage (Solomon et al. 2004a), However,
treatment coverage is not the sole key to success. In a
low-prevalence setting in The Gambia, significant
re-infection in two villages post-treatment was observed,
despite treatment coverage being 86% and 92%. This was
attributed to a mass migration event where virtually the
entire population of these two communities attended a
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religious festival in Senegal shortly after being treated
(Burton et al. 2005b). In one Ethiopian study, an overall
treatment coverage of 91.9% was achieved, but was
followed by a 12.3% exponential rate of return of infection
(Melese et al. 2004b). Also in Ethiopia, it was demon-
strated that although treatment coverage was important in
determining the prevalence of ocular C. trachomatis infec-
tion at 2 months post-treatment, coverage was no longer a
predictor of infection at 6 months (Lakew et al. 2009a).
Factors found to affect the acceptability of azithromycin
are local prevention norms (for example, believing that
injections are better than oral medicine), perceptions of the
distribution team’s expertise, witnessing adverse effects
in others, and the timing, quality and quantity of infor-
mation provided. Therefore, to maximise coverage, it is
important to understand the community’s perceptions,
conduct a pre-distribution assessment and community
education, provide advance notice of the distribution,
build a good relationship with the community, create and
follow standardised distribution guidelines, and improve
distributor training (Desmond et al. 2005).
How often should mass treatment be given?
It has been argued that a single round of mass treatment,
with high coverage, may reduce the prevalence of infection
to below a threshold at which it cannot persist, and from
which it cannot return. This is known as the Allee effect
(Chidambaram et al. 2005). Alternatively, mass treatment
may eliminate some strains of C. trachomatis from the
community, reducing the antigenic diversity which may
enable the bacteria to evade the human immune system,
and this less diverse population may never re-attain a high
prevalence (Zhang et al. 2004b; Burton et al. 2005b;
Chidambaram et al. 2006; Andreasen et al. 2008). Factors
affecting the success of a single round of mass treatment
are the baseline prevalence, treatment coverage, treatment
efficacy in the individual, whether ‘F’ and ‘E’ component
measures are in place, and the amount of in- and out-
migration (Lietman et al. 1999; Gaynor et al. 2003b;
Burton et al. 2005b; Chidambaram et al. 2006).
A single round of mass azithromycin treatment was
successful in reducing the prevalence of ocular C. tracho-
matis infection from 9.5% at baseline to 0.1% at 2 years in
a Tanzanian community (Solomon et al. 2004a). After a
second round of mass treatment at 2 years, infection was
eliminated by 5 years post-baseline (Solomon et al. 2008).
This demonstrates that antibiotic treatment alone can
result in elimination, as no ‘F’ or ‘E’ interventions were
introduced. However, the baseline treatment coverage of
97.8% far exceeds that which would normally be achieved
under operational conditions. The decline in trachoma
prevalence may not have been a result solely of the mass
azithromycin treatment as tetracycline eye ointment was
distributed at the 6, 12 and 18 month follow-ups to
individuals with active disease. However, 15–100% of the
community ocular C. trachomatis load at each of the final
three follow-ups was found in participants who had
received tetracycline in the previous follow-up, indicating
tetracycline treatment did not play a major role in the
observed prevalence decline. Alternatively, random fluctu-
ation, seasonal effects, secular trend and regression to the
mean may have contributed to the outcome. In contrast,
two rounds of mass azithromycin treatment (at baseline
and 18 months) in a different Tanzanian village did not
eliminate active disease or C. trachomatis infection 5 years
post-baseline (West et al. 2007b). In fact, although the
infection rate declined between baseline and 18 months,
the prevalence of infection was higher at the 5-year follow-
up than at 18 months in all age groups.
Several studies have reported moderate success of one
round of antibiotic treatment, with infection initially
falling immediately post-treatment, but increasing (albeit
to a lower prevalence than at baseline) within 12 months
of treatment. In Egypt, The Gambia and Tanzania, it was
observed that the prevalence of infection at 1 year after
mass treatment was substantially lower than at baseline,
but was higher than the prevalence at the 3-month follow-
up (Schachter et al. 1999). Similar results of an initial
reduction in infection with re-emergence approximately
1 year after treatment, but which does not return to pre-
treatment levels by 2 years, have been reported by others in
high-prevalence settings (Melese et al. 2004b; West et al.
2005b; Chidambaram et al. 2006; Lakew et al. 2009b).
A study of 14 Gambian villages demonstrated that in low
or medium prevalence areas, a single round of mass
azithromycin treatment could lead to long-term control of
infection, but that monitoring is required because of
re-infection (Burton et al. 2003, 2005b). To help overcome
the risk of re-infection from migration, it has been
recommended that broader geographical areas should be
treated, and people who have immigrated into the village
should be treated after the initial mass treatment (Schach-
ter et al. 1999; Burton et al. 2005b).
The aforementioned studies demonstrate that the effect
of a single round of mass azithromycin treatment is
heterogeneous, with some communities experiencing
elimination of infection whereas others observe rapid
re-emergence. In fact, more frequent treatment distribu-
tions could be beneficial in high-prevalence settings.
Mathematical modelling has shown that where the prev-
alence of active disease is >50% in children, bi-annual
treatment could eliminate disease (Lietman et al. 1999).
Where disease prevalence is <35%, treatment annually or
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every 2 years would suffice. Mathematical simulations
for elimination of infection in Ethiopia suggest that 5 years
of biannual treatment would lead to elimination in 95% of
all villages (Ray et al. 2007). Data from Ethiopia demon-
strated that the prevalence of infection at 24 months was
significantly lower in villages treated biannually than in
villages treated annually (Melese et al. 2008).
As a result of the re-emergence of infection in these
studies, there is empirical evidence to support the need for
repeated antibiotic treatment. Mathematical modelling has
suggested that treatment could be stopped once the
prevalence of infection has fallen below 5% (Ray et al.
2009). Socio-economic improvements may then allow the
disease to be permanently eliminated without the need for
further treatment. This is the rationale adopted by the
WHO in their advocacy of the SAFE strategy. However, if
the ‘F’ and ‘E’ components of the SAFE strategy do not
have a strong enough effect, the prevalence of infection
may return to pre-intervention level (Gaynor et al. 2002).
Facial cleanliness
Improving facial cleanliness (the absence of ocular and
nasal discharge) (Negrel & Mariotti 1999) aims to reduce
auto-transmission and transmission to others by removing
a potential source of infection (Kuper et al. 2003). It is
promoted through health education and improved water
supply, but the evidence-base for this control strategy is
limited. As discussed previously, gaining information on
face washing is difficult, as the validity of self-reporting is
questionable, measures of a clean face are subjective and
certain indicators (discharge and flies) are more reliable
than others (dust and food on the face) (Harding-Esch
et al. 2008; Zack et al. 2008). Observational data indicate
there is an association between having a clean face and not
having trachoma but, as already mentioned, this does not
establish a causal relationship.
A cross-sectional study in Mexico reported that the
frequency of face washing (>7 times a week) was negatively
correlated with the likelihood of children having active
disease (Taylor et al. 1985). Peach et al. conducted a
randomised trial comparing four groups: a control group
(no intervention), eye washing only, tetracycline eye
ointment only and tetracycline combined with eye wash-
ing. At 3 months, there was no significant benefit to eye
washing, either alone or in combination with treatment
(Peach et al. 1987). In Tanzania, an educational interven-
tion to keep children’s faces clean was implemented, and
the number of clean pre-school children’s faces was
recorded. There was an increase in the percentage of clean
faces from 9% at baseline to 33% at 1 year (Lynch et al.
1994). Subsequently, the only randomised controlled trial
of face washing compared mass tetracycline treatment with
mass tetracycline treatment combined with a face-washing
programme (West et al. 1995). Screening was performed at
baseline, 6 and 12 months post-baseline. Children who
received both the face-washing programme and treatment
were more likely to have sustained clean faces than those
who only received treatment, although the difference was
not significant (OR 1.61, 95% CI 0.94–2.74). However,
65% of children in the intervention group still had a dirty
face at two or more follow-ups. The risk of having severe
trachoma (defined as the presence of ‡15 follicles or the
presence of inflammation that obscured all tarsal plate
vessels) in the face-washing group after 1 year was signif-
icantly lower than the treatment-only group (OR 0.62,
0.40–0.94), as mentioned previously. However, there was
no difference in the overall prevalence of active disease
between the two arms. The programme was labour
intensive and expensive.
Environmental improvement
The ‘E’ component of the SAFE strategy aims to reduce
transmission of C. trachomatis by promoting better per-
sonal and environmental hygiene. The elimination of
trachoma from Europe and North America in the 19th
century in the absence of any specific intervention, dem-
onstrates the importance of environmental improvement
components of the SAFE strategy (Mabey et al. 2003).
Through increasing water supply and quality, improving
access to latrines, decreasing fly density, reduced crowding
and providing health education, transmission of trachoma
should be interrupted (Kuper et al. 2003).
Resnikoff et al. compared health education alone, mass
tetracycline treatment alone, health education combined
with tetracycline treatment, and a control group (no
intervention), assigning only one village to each arm
(Resnikoff et al. 1995). They found that at 6 months, the
incidence of active disease was lower in the health education
only group compared with the control group. However,
there was no value in the addition of health education to
mass treatment, with mass treatment alone producing the
best results in terms of cure rate and lower incidence.
There was little evidence for the fly control component
of the SAFE strategy until Emerson et al. demonstrated
that insecticide spraying in The Gambia led to an overall
and significant 61% lower community prevalence of active
disease, a reduction of 75% in the M. sorbens fly popu-
lation, and a 96% reduction in fly-eye contacts in the
intervention villages at 3 months (Emerson et al. 1999).
However, the study only compared two pairs of villages
and was open to bias. In 2004, Emerson et al.compared
seven clusters that received spraying with seven that did
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not. Insecticide spraying led to an 88% decrease in fly-eye
contacts and a significant 55.8% reduction in the preva-
lence of active disease in the intervention clusters (Emerson
et al. 2004). West et al. randomised 16 Tanzanian com-
munities to receive a single round of mass azithromycin
treatment (control group) or to receive azithromycin and
frequent rounds of insecticide spraying (intervention
group) (West et al. 2006b). In contrast to the previous
studies, they found no difference in the prevalence of active
disease at either 6 or 12 months post-baseline, or of
C. trachomatis infection at 6 months, between interven-
tion and control communities, despite the mean prevalence
of flies being significantly lower in the intervention group.
Furthermore, spraying is labour intensive, expensive and
not sustainable (Rabiu et al. 2007).
Only one randomised controlled trial examining latrine
use exists. Emerson et al. compared seven clusters that
received latrines, with seven that did not (Emerson et al.
2004). Latrine provision resulted in a 30% decrease in
M. sorbens-eye contacts, and an associated 29.5% reduc-
tion in trachoma prevalence, which did not reach statistical
significance, despite latrine use reported to be 98%.
Latrines will only improve environmental sanitation if they
are used consistently by a large proportion of the
community. Therefore, latrine provision should be in
accordance with what already exists and what is acceptable
in the community (WHO, 2006).
The SAFE Strategy: putting the pieces together
Although the individual components of the SAFE strategy
have demonstrated success in controlling trachoma, it is
through the implementation of all four elements together
that this control strategy is expected to have most success.
Some studies have evaluated the combined effect of
multiple components of the SAFE strategy. A cross-
sectional analysis of implementation of the A, F and E
components in Ethiopia demonstrated that receiving three
rounds of azithromycin treatment, having a clean face, and
increased face-washing frequency, were independently
associated with a reduced prevalence of active disease in
children (Ngondi et al. 2008). Thus, implementation of the
different SAFE components would have an additive effect
in trachoma control.
Implementation of the entire SAFE strategy in five
Ethiopian districts showed that uptake of all components
was high by the 3-year evaluation time-point (Ngondi et al.
2009a). The declines in TF, TI and unclean face prevalence
in children aged 1–9 were statistically significant, and the
prevalence of TT significantly decreased in three of the
districts. The overall prevalence of ocular C. trachomatis
infection at 3 years was 3.1%, but was higher in districts
last treated over a year ago (4.3%) and lower in those
treated recently (1.4%), suggesting on-going transmission.
In Zambia, introduction of SAFE measures led to a
reduction in the prevalence of total trachoma in children
under 10 years from 55% at baseline to 10.6% at 2 years.
The prevalence of TF fell from 24.9% to 4.5% in children,
and the prevalence of TT in adults fell from 0.6% to 0.3%
(Astle et al. 2006). However, in the absence of control
groups, secular trend cannot be excluded as an explana-
tion. In addition, without investigating these interventions
through a randomised controlled trial, the relative impact
of each component cannot be elucidated.
In Sudan, a control area was included with which to
compare four areas in which the SAFE strategy had been
implemented. The evaluation at 3 years showed heteroge-
neous uptake of interventions and results. All four inter-
vention areas experienced declines in the prevalence of TF,
TI and unclean faces. This was substantial in two of the
areas, moderate in one, and non-significant in one, com-
pared with the control. The decline in active disease was
most likely attributable to antibiotic treatment and
improved facial cleanliness was a result of hygiene health
education combined with water provision, as the greatest
trachoma declines were achieved where uptake of these
activities was highest (Ngondi et al. 2006c). In Ethiopia,
Cumberland et al. conducted a trial where 40 communities
were randomised to either health promotion by national
radio only (control); mass azithromycin treatment and
radio; mass treatment, radio and information, education
and communication (IEC) materials; or mass treatment,
radio, IEC and community video and drama shows
(Cumberland et al. 2008). The exact allocation schedule
was unable to be followed, but the 3 year evaluation
demonstrated a significantly reduced risk of active disease
in communities given antibiotics combined with IEC (OR
0.35, 95% CI 0.13–0.89), and in communities additionally
receiving video health messages (OR 0.31, 0.11–0.89).
Similarly, the risk of having ocular C. trachomatis infec-
tion was significantly lower in these two intervention
groups. Although antibiotic treatment was identified as
being the most active component for all outcomes, the
addition of health education was beneficial.
Conclusion
Blinding trachoma disappeared from Western Europe and
North America at the beginning of the 20th century, yet it
continues to cause an enormous burden of disease in poor
rural communities in the developing world. There have
been encouraging reductions in the prevalence of active
disease in many countries in the past 20 years. However, a
large backlog of unoperated trichiasis cases which remains
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in many countries will have to be addressed by national eye
care programmes if blinding trachoma is to be eliminated
by 2020.
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